Discover how hypertension, diabetes, atrial fibrillation, high cholesterol, and obesity increase stroke risk, and learn ...
Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...
Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...
Research predicts stroke deaths may rise 50% globally by 2050, with younger people increasingly affected. Learn effective ...
The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.
According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...
The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...
Ischemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...
A molecule called glial fibrillary acidic protein (GFAP) rose significantly in the blood of patients who underwent ...
Popovich has not coached since suffering what the Spurs described as a “mild stroke” on Nov. 2. His status for next season is ...